Monday, December 10, 2007
Patients transitioning from amaryl.
Patients transitioning from pioglitazone monotherapy should receive an initial dose of 30 mg/2 mg while those currently receiving glimepiride monotherapy can be started on either the 30-mg/2-mg or 30-mg/4-mg dose.
Because no exact medicinal drug family relationship exists between amaryl and other sulfonylureas, patients taking a different sulfonylurea alone or with pioglitazone should be limited to the lower starting dose of the alignment slab.Patients should be observed carefully for hypoglycemia during transitions between drugs and dosages of pioglitazone and glimepiride, particularly when shifting from sulfonylureas that have a longer half-life than amaryl.
Serum alanine aminotransferase levels should be obtained at standard and periodically thereafter; management should be discontinued if alanine aminotransferase values exceed 3 period the berth extent of normal or the case has thorniness.
Because thiazolidinediones, such as amaryl, can crusade ovulation in some premenopausal anovulatory women, the need for adequate contraceptive measures should be emphasized.The FDA has approved a new denotation for adalimumab intromission, allowing its use for the aid of severe, soul ankylosing spondylitis.
As with the aid of rheumatoid and psoriatic arthritis, the recommended dose of adalimumab for ankylosing spondylitis is 40 mg administered subcutaneously every other week.
The blessing was based on clinical tribulation data viewing that 42% of adalimumab-treated patients vs 16% of those receiving medication achieved a change of magnitude of 50% or more in disease activeness at week 24, as evaluated by the Bath AS Disease Trait Finger.
Adalimumab-treated patients also achieved a mean 50% alteration in enthesitis grounds scores.
Medscape Medical News 2006. ©2006 Medscape
Legal Renunciation The stuff presented here does not necessarily reflect the views of Medscape or companies that livelihood educational creating by mental acts on www.medscape.com.
These materials may discuss therapeutic products that have not been approved by the US Food and Drug Tenure and off-label uses of approved products.
A qualified healthcare authority should be consulted before using any therapeutic outcome discussed.
Readers should verify all selective information and data before treating patients or employing any therapies described in this educational body process.
This is a part of article Patients transitioning from amaryl. Taken from "Generic Amaryl (Glimepiride) Information" Information Blog
Labels: pharmacology
